International Development Grant
Support to COVID-19 therapeutics
Project Number: CA-3-P009758001
Status: Closed
Country/Region: Unknown
Regional Focus:
Maximum Contribution: $15,000,000.00
Start Date: March 30, 2021
End Date: March 31, 2023
Duration: 2.0 years
Project Description
This project aims to advance equitable and affordable access to the most promising COVID-19 treatments in lower-income countries and lower-middle-income countries (LMICs). The project supports Unitaid in securing manufacturing capacity and supply for relevant treatments including monoclonal antibodies novel antivirals and medical oxygen. This project contributes to the Access to COVID-19 Tools (ACT) -– Accelerator Therapeutics Partnership objectives. Project activities include: (1) increasing access to medical oxygen ; (2) improving supply security across sub-Saharan Africa through market interventions; and (3) piloting the introduction feasibility and acceptability of innovations in at least 5 countries.
Expected Results
The expected outcomes of the project include: (1) increased capacity of oxygen produced and delivered to low- and lower-middle income countries; (2) an expanded portfolio of fit-for-purpose new therapeutics adapted for LMICs; and (3) ensured availability and affordability of therapeutics and a related package of care in low- and lower-middle income countries.
Key Information
Executing Agency:
WHO - World Health Organization
Reporting Organization:
Global Affairs Canada
Program:
YFMInternaAssistPartnershp&Programing Br
Last Modified:
September 19, 2025
Development Classifications
DAC Sector:
Aid Type: Contributions to specific-purpose programmes and funds managed by implementing partners
Collaboration: Bilateral
Finance Type: Aid grant excluding debt reorganisation
Selection Mechanism:
Department-Initiated